Innostellar Biotherapeutics Co.,ltd

This early-stage study is testing a new gene therapy, called LX101, for people with a rare inherited eye disease that causes vision loss. The therapy involves a single injection into the eye to deliver a working copy of a faulty gene. Researchers are primarily checking if the tre…

This study is testing whether a one-time gene therapy injection (called LX101) can improve vision in people with a specific inherited retinal disease that causes blindness. The trial involves 30 participants, aged 6 and older, who have vision loss due to mutations in the RPE65 ge…

This study is testing whether a single gene therapy injection (LX102) can help control wet age-related macular degeneration, potentially reducing the need for frequent eye injections. It compares two doses of the experimental therapy against the current standard treatment in 50 p…